Detalhe da pesquisa
1.
Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.
Br J Haematol
; 178(2): 196-208, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466550
2.
Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.
Stem Cells
; 33(4): 1359-65, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25537496
3.
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
medRxiv
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38699307
4.
Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression.
Blood Adv
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513135
5.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.
Cancer Discov
; 13(2): 348-363, 2023 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477267
6.
Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
Nat Rev Clin Oncol
; 19(4): 223-236, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35017721
7.
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Cancer Cell
; 40(11): 1358-1373.e8, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379208
8.
Resilin-mimetics as a smart biomaterial platform for biomedical applications.
Nat Commun
; 12(1): 149, 2021 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33420053
9.
Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
Leukemia
; 33(2): 457-468, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30046162
10.
Using genomics to better define high-risk MGUS/SMM patients.
Oncotarget
; 9(93): 36549-36550, 2018 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30564295